RIGI Recombinant Antibody

$THP-1 (H) cells were treated with or without LPS (1ug\/ml) for overnight, 25 \u03bcg total protein per lane of cell lysates (see on figure) probed with RIGI monoclonal antibody, unconjugated (bsm-61573R) at 1:1000 dilution and 4\u00b0C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.$

THP-1 (H) cells were treated with or without LPS (1ug\/ml) for overnight, 25 \u03bcg total protein per lane of cell lysates (see on figure) probed with RIGI monoclonal antibody, unconjugated (bsm-61573R) at 1:1000 dilution and 4\u00b0C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.

Applications

Reactivity

Human

Overview
Catalog #	bsm-61573r
Product Name	RIGI Recombinant Antibody
Applications	WB, IP
Reactivity	Human
Specifications
Conjugation	Unconjugated
Host	Rabbit
Source	KLH conjugated synthetic peptide derived from human RIGI
Clonality	Recombinant
Isotype	IgG
Concentration	Lot dependent
Purification	Purified by Protein A.
Storage Buffer	0.01M TBS (pH 7.4), 1% BSA, 0.02% Proclin 300, and 50% Glycerol
Storage Condition	Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles.
Target
Gene ID	23586
Swiss Prot	O95786
Synonyms	RIG-I-like receptor 1; RLR-1; RLR1; Retinoic acid-inducible gene 1 protein; RIG-1; RIG1; RIG-I; RIGI.
Background	Innate immune receptor that senses cytoplasmic viral nucleic acids and activates a downstream signaling cascade leading to the production of type I interferons and pro-inflammatory cytokines.
Application Dilution
WB	1:500-2000
IP	IP1:20-50